Lenvatinib ‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis
Oncol Lett. 2024 Apr 12;27(6):265. doi: 10.3892/ol.2024.14398. eCollection 2024 Jun.ABSTRACTHepatocellular carcinoma (HCC) is a malignancy associated with high morbidity and mortality rates. Conversion therapy provides patients with unresectable HCC (uHCC) the opportunity to undergo radical treatment and achieve long-term survival. Despite accumulating evidence regarding the efficacy of conversion therapy, the optimal treatment approach for such therapy remains uncertain. Lenvatinib (LEN) has shown efficacy and tolerable rates of adverse events (AEs) when applied in combination with immune checkpoint inhibitors (ICIs) or l...
Source: Oncology Letters - April 25, 2024 Category: Cancer & Oncology Authors: Saixin Li Zeyu Zhang Zheng Wang Kenan Wang Minghao Sui Dongbin Liu Kuo Liang Source Type: research
Feasibility Study of Computed Tomographic Radiomics Model for the Prediction of Early and Intermediate Stage Hepatocellular Carcinoma Using BCLC Staging
CONCLUSION: The CT radiomic model can be used to predict the BCLC stage of early-stage and intermediate-stage HCC.PMID:38660703 | PMC:PMC11044781 | DOI:10.1177/15330338241245943 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - April 25, 2024 Category: Cancer & Oncology Authors: Han Dong Lu Yang Duan Shaofeng Guo Lili Source Type: research
Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression
Int Rev Cell Mol Biol. 2024;385:41-99. doi: 10.1016/bs.ircmb.2023.11.006. Epub 2024 Jan 15.ABSTRACTGastrointestinal carcinomas are a group of cancers associated with the digestive system and its accessory organs. The most prevalent cancers related to the gastrointestinal tract are colorectal, gall bladder, gastric, hepatocellular, and esophageal cancers, respectively. Molecular aberrations in different signaling pathways, such as signal transduction systems or developmental pathways are the chief triggering mechanisms in different cancers Though a massive advancement in diagnostic and therapeutic interventions results in i...
Source: International Review of Cell and Molecular Biology - April 25, 2024 Category: Cytology Authors: Afza Ahmad Rohit Kumar Tiwari Saleha Siddiqui Muskan Chadha Ratnakar Shukla Vivek Srivastava Source Type: research
Interim analysis of the PARADISE study: benefits of add-on peginterferon- α in NA-treated patients with CHB
This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients with chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB patients with intermediate to high risk of HCC after more than 24-week NAs pretreatment were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group maintained NAs monotherapy, while IFN+NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monothe...
Source: Antiviral Research - April 25, 2024 Category: Virology Authors: Shaowen Jiang Simin Guo Yan Huang Jie Xu Yi Li Yilan Zeng Yuan Guo Lijuan Ouyang Chuanwu Zhu Weifeng Zhao Qin Zhang Qing Guo Haiguang Xin Qing Xie Source Type: research
Synthesis and evaluation of pentacyclic triterpenoids conjugates as novel HBV entry inhibitors targeting NTCP receptor
In this study, pentacyclic triterpenoids (PTs) including glycyrrhetinic acid (GA), oleanolic acid (OA), ursolic acid (UA) and betulinic acid (BA) were modified via molecular hybridization with podophyllotoxin respectively, and resulted in thirty-two novel conjugates. The anti-HBV activities of conjugates were evaluated in HepG2.2.15 cells. The results showed that 66% of the conjugates exhibited lower toxicity to the host cells and had significant inhibitory effects on the two HBV antigens, especially HBsAg. Notably, the compounds BA-PPT1, BA-PPT3, BA-PPT4, and UA-PPT3 not only inhibited the secretion of HBsAg but also supp...
Source: Bioorganic Chemistry - April 25, 2024 Category: Chemistry Authors: Yixin Chen Meitao Duan Xiangwan Wang Jianling Xu Shuo Tian Xiaotian Xu Ao Duan Ahmed Mahal Yongyan Zhu Quanhong Zhu Source Type: research
Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression
Int Rev Cell Mol Biol. 2024;385:41-99. doi: 10.1016/bs.ircmb.2023.11.006. Epub 2024 Jan 15.ABSTRACTGastrointestinal carcinomas are a group of cancers associated with the digestive system and its accessory organs. The most prevalent cancers related to the gastrointestinal tract are colorectal, gall bladder, gastric, hepatocellular, and esophageal cancers, respectively. Molecular aberrations in different signaling pathways, such as signal transduction systems or developmental pathways are the chief triggering mechanisms in different cancers Though a massive advancement in diagnostic and therapeutic interventions results in i...
Source: Mol Biol Cell - April 25, 2024 Category: Molecular Biology Authors: Afza Ahmad Rohit Kumar Tiwari Saleha Siddiqui Muskan Chadha Ratnakar Shukla Vivek Srivastava Source Type: research
Aflatoxin B < sub > 1 < /sub > -exposed hepatocyte-derived extracellular vesicles: Initiating hepatic stellate cell-mediated liver fibrosis through a p53-Parkin-dependent mitophagy pathway
This study further revealed that the hepatic fibrogenesis of AFB1 exposure was rescued by genetic intervention with siPARK2 or p53's Pifithrin-α (PFTα) inhibitors. Furthermore, AFB1-EVs-induced HSCs activation was relieved by GW4869 pharmaceutic inhibition of EVs secretion. These results revealed a novel mechanism that AFB1 exposure-induced p53-Parkin signal axis regulated mitophagy-dependent hepatocyte-derived EVs to mediate the mitochondria-trafficking intercellular communication between hepatocytes and HSCs in the local hepatotoxic microenvironment to promote the activated HSCs-associated liver fibrogenesis. Our study...
Source: Ecotoxicology and Environmental Safety - April 25, 2024 Category: Environmental Health Authors: Lei Yang Yun-Lu Gao Shan Jiang Bo Qian Lin Che Jia-Shen Wu Ze-Bang Du Ming-Zhu Wang Yun Yang Yu-Chun Lin Gang Liu Zhong-Ning Lin Source Type: research
FDG PET/CT Imaging of Sarcomatoid Hepatocellular Carcinoma ：A case report
Asian J Surg. 2024 Apr 24:S1015-9584(24)00721-8. doi: 10.1016/j.asjsur.2024.04.061. Online ahead of print.NO ABSTRACTPMID:38664188 | DOI:10.1016/j.asjsur.2024.04.061 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - April 25, 2024 Category: Surgery Authors: Zhiyan Chen He Wang Xiangrong Yu Source Type: research
Feasibility Study of Computed Tomographic Radiomics Model for the Prediction of Early and Intermediate Stage Hepatocellular Carcinoma Using BCLC Staging
CONCLUSION: The CT radiomic model can be used to predict the BCLC stage of early-stage and intermediate-stage HCC.PMID:38660703 | PMC:PMC11044781 | DOI:10.1177/15330338241245943 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - April 25, 2024 Category: Cancer & Oncology Authors: Han Dong Lu Yang Duan Shaofeng Guo Lili Source Type: research
Lenvatinib ‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis
Oncol Lett. 2024 Apr 12;27(6):265. doi: 10.3892/ol.2024.14398. eCollection 2024 Jun.ABSTRACTHepatocellular carcinoma (HCC) is a malignancy associated with high morbidity and mortality rates. Conversion therapy provides patients with unresectable HCC (uHCC) the opportunity to undergo radical treatment and achieve long-term survival. Despite accumulating evidence regarding the efficacy of conversion therapy, the optimal treatment approach for such therapy remains uncertain. Lenvatinib (LEN) has shown efficacy and tolerable rates of adverse events (AEs) when applied in combination with immune checkpoint inhibitors (ICIs) or l...
Source: Oncology Letters - April 25, 2024 Category: Cancer & Oncology Authors: Saixin Li Zeyu Zhang Zheng Wang Kenan Wang Minghao Sui Dongbin Liu Kuo Liang Source Type: research
Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression
Int Rev Cell Mol Biol. 2024;385:41-99. doi: 10.1016/bs.ircmb.2023.11.006. Epub 2024 Jan 15.ABSTRACTGastrointestinal carcinomas are a group of cancers associated with the digestive system and its accessory organs. The most prevalent cancers related to the gastrointestinal tract are colorectal, gall bladder, gastric, hepatocellular, and esophageal cancers, respectively. Molecular aberrations in different signaling pathways, such as signal transduction systems or developmental pathways are the chief triggering mechanisms in different cancers Though a massive advancement in diagnostic and therapeutic interventions results in i...
Source: International Review of Cell and Molecular Biology - April 25, 2024 Category: Cytology Authors: Afza Ahmad Rohit Kumar Tiwari Saleha Siddiqui Muskan Chadha Ratnakar Shukla Vivek Srivastava Source Type: research
Interim analysis of the PARADISE study: benefits of add-on peginterferon- α in NA-treated patients with CHB
This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients with chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB patients with intermediate to high risk of HCC after more than 24-week NAs pretreatment were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group maintained NAs monotherapy, while IFN+NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monothe...
Source: Antiviral Research - April 25, 2024 Category: Virology Authors: Shaowen Jiang Simin Guo Yan Huang Jie Xu Yi Li Yilan Zeng Yuan Guo Lijuan Ouyang Chuanwu Zhu Weifeng Zhao Qin Zhang Qing Guo Haiguang Xin Qing Xie Source Type: research
Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression
Int Rev Cell Mol Biol. 2024;385:41-99. doi: 10.1016/bs.ircmb.2023.11.006. Epub 2024 Jan 15.ABSTRACTGastrointestinal carcinomas are a group of cancers associated with the digestive system and its accessory organs. The most prevalent cancers related to the gastrointestinal tract are colorectal, gall bladder, gastric, hepatocellular, and esophageal cancers, respectively. Molecular aberrations in different signaling pathways, such as signal transduction systems or developmental pathways are the chief triggering mechanisms in different cancers Though a massive advancement in diagnostic and therapeutic interventions results in i...
Source: Mol Biol Cell - April 25, 2024 Category: Molecular Biology Authors: Afza Ahmad Rohit Kumar Tiwari Saleha Siddiqui Muskan Chadha Ratnakar Shukla Vivek Srivastava Source Type: research
Synthesis and evaluation of pentacyclic triterpenoids conjugates as novel HBV entry inhibitors targeting NTCP receptor
In this study, pentacyclic triterpenoids (PTs) including glycyrrhetinic acid (GA), oleanolic acid (OA), ursolic acid (UA) and betulinic acid (BA) were modified via molecular hybridization with podophyllotoxin respectively, and resulted in thirty-two novel conjugates. The anti-HBV activities of conjugates were evaluated in HepG2.2.15 cells. The results showed that 66% of the conjugates exhibited lower toxicity to the host cells and had significant inhibitory effects on the two HBV antigens, especially HBsAg. Notably, the compounds BA-PPT1, BA-PPT3, BA-PPT4, and UA-PPT3 not only inhibited the secretion of HBsAg but also supp...
Source: Bioorganic Chemistry - April 25, 2024 Category: Chemistry Authors: Yixin Chen Meitao Duan Xiangwan Wang Jianling Xu Shuo Tian Xiaotian Xu Ao Duan Ahmed Mahal Yongyan Zhu Quanhong Zhu Source Type: research
Lenvatinib ‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis
Oncol Lett. 2024 Apr 12;27(6):265. doi: 10.3892/ol.2024.14398. eCollection 2024 Jun.ABSTRACTHepatocellular carcinoma (HCC) is a malignancy associated with high morbidity and mortality rates. Conversion therapy provides patients with unresectable HCC (uHCC) the opportunity to undergo radical treatment and achieve long-term survival. Despite accumulating evidence regarding the efficacy of conversion therapy, the optimal treatment approach for such therapy remains uncertain. Lenvatinib (LEN) has shown efficacy and tolerable rates of adverse events (AEs) when applied in combination with immune checkpoint inhibitors (ICIs) or l...
Source: Oncology Letters - April 25, 2024 Category: Cancer & Oncology Authors: Saixin Li Zeyu Zhang Zheng Wang Kenan Wang Minghao Sui Dongbin Liu Kuo Liang Source Type: research
